What are people really saying about your big project?
Europe’s Very Own Formula for Productivity & Innovation
Are you feeling upbeat about big pharma? Or is Chinese Pharma on your mind? Our research for a new book points to 5 factors, often overlooked, that underpin the competitive advantage of players like Merck, Roche, AstraZeneca and Pfizer.
The threat of Chinese pharma and the prospects of a US-China trade war have been stealing the headlines. The warning is that some of big pharma’s blockbuster drugs could be at risk. That Chinese innovation could outpace that of the industry’s biggest players. But, how real is the threat?
Could the Chinese dragon going to do serious damage to big pharma?
We turned to the research in our new book, Pharma Super Projects, for insights into how big pharma is likely to respond to Chinese and other threats at this fascinating time in the industry.
Here are five insights from Super Projects on how big pharma is executing on its big projects and ambitious strategies.
With massive investments in R&D, the industry is doubling down on confidence and ambition regarding its future.
Analysts warn of underestimating Chinese pharma. However, the message from Super Projects is: Don’t underestimate big pharma either.
Don’t underestimate its people. At the coalface in big pharma, you will find its secret weapon. That is an army of talented, passionate, and relentless action heroes who are making ambitious projects and strategies happen, even in the face of obstacles and setbacks.
Some worry that big pharma is too big and too slow. But there is a new operating model, centered on cross-functional teams empowered to make things happen.
This productivity hack is capable of delivering surprising levels of speed, agility, and innovation.
R&D productivity has been a key focus for big pharma, with some room for optimism, especially in respect of R&D performance. These people-related aspects of R&D have the potential to save hundreds of millions.
Despite the need to replenish pipelines, progression isn’t always the goal. Indeed, stopping some projects early is key to pipeline success.
Creating environments where people are empowered to ‘call it early’ can save hundreds of millions.
That is just five of the insights into big pharma’s super projects.Those projects reveal just what the industry is capable of, especially when faced with big challenges ranging from the patent cliff to Chinese entrants.
Super Projects is a celebration of big pharma, its super projects, and the heroes who are making them happen.
Do you want to read their story or share your own?
Join us for a free WEBINAR:
Would you like to participate in or sponsor this research?
Super Projects (www.superprojects.co) is an industry-wide research initiative funded by Growth Pitstop (www.growthpitstop.com). It aims to instill greater C-suite pride in banking transformation and other big projects or initiatives. Moreover, to celebrate those leading big projects as the new organizational heroes.
www.Super-Projects.co
Sponsored by Growth Pitstop
SOLUTIONS & SERVICES: Here are some of the ways that our research & insights are put to work by our clients:
